PDCD1 and cancer: Notably, often less than 20% of patients respond to a single immunotherapy, including common cancer types like breast, colon and prostate cancer (4), and hence the urgent need to combine therapies, for example by using antibodies against PD-L1, CTLA-4 and/or PD-1 (4).